Management of Hepatic Complications in HIV-Infected Persons

Sulkowski, Mark S.
May 2008
Journal of Infectious Diseases;5/15/2008 Supplement 3, pS279
Academic Journal
In the era of effective antiretroviral therapy (ART), liver disease is the second most common cause of death among persons with human immunodeficiency virus (HIV) infection. Liver disease-related deaths mostly result from chronic infection with hepatitis B virus (HBV) and/or hepatitis C virus (HCV). In addition, recent reports suggest that HCV infection may be transmitted sexually between HIV-infected men who have sex with men. Management of these conditions in HIV-infected persons requires careful consideration, balancing the potential benefits of therapy with the potential for significant treatment-related adverse effects (HCV infection) and viral resistance and/or hepatitis flares (HBV infection). Furthermore, several antiretroviral agents are active against HBV infection, including lamivudine, emtricitabine, tenofovir, and, more recently, entecavir. Despite the complexity and potential for antiretroviral-associated hepatotoxicity, ART usually is safe for patients with viral hepatitis coinfection, and, in some cases, treatment for HIV infection may be beneficial for the liver.


Related Articles

  • Forgiveness of non-adherence to HIV-1 antiretroviral therapy.  // Journal of Antimicrobial Chemotherapy (JAC);Apr2008, Vol. 61 Issue 4, p769 

    Superior adherence to HIV-1 antiretroviral therapy is a mainstay of successful HIV management. Studies performed in the early era of highly active antiretroviral therapy demonstrated the need for ≥95% adherence in order to achieve and sustain viral suppression. High rates of viral...

  • Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis. J. A. Pineda; J. Santos; A. Rivero; L. Abdel-Kader; R. Palacios; A. Camacho; F. Lozano; J. Macías; on behalf of the Liverey Study Investigator Team // Journal of Antimicrobial Chemotherapy (JAC);Apr2008, Vol. 61 Issue 4, p925 

    Objectives To appraise the rate of grade 3–4 transaminase elevations (TEs) and grade 4 total bilirubin elevation (TBE) in patients co-infected with human immunodeficiency virus (HIV) and hepatitis C or hepatitis B virus (HCV or HBV, respectively) who receive atazanavir/ritonavir....

  • Phase II Study of Vicriviroc versus Efavirenz (both with Zidovudine/Lamivudine) in Treatment-Naive Subjects with HIV-1 Infection. Landovitz, Raphael J.; Angel, Jonathan B.; Hoffmann, Christian; Horst, Heinz; Opravil, Milos; Long, Jianmin; Greaves, Wayne; Fätkenheuer, Gerd // Journal of Infectious Diseases;10/15/2008, Vol. 198 Issue 8, p1113 

    Background. Vicriviroc (VCV) is a CCR5 antagonist with nanomolar activity against human immunodeficiency virus (HIV) replication in vitro and in vivo. We report the results of a phase II dose-finding study of VCV plus dual nucleoside reverse-transcriptase inhibitors (NRTIs) in the...

  • CD4+ Count—Guided Interruption of Antiretroviral Treatment.  // New England Journal of Medicine;11/30/2006, Vol. 355 Issue 22, p2283 

    Background: Despite declines in morbidity and mortality with the use of combination antiretroviral therapy, its effectiveness is limited by adverse events, problems with adherence, and resistance of the human immunodeficiency virus (HIV). Methods: We randomly assigned persons infected with HIV...

  • Efectos del tiempo de infección sobre predictores de adherencia en personas con VIH. Piña López, Julio Alfonso; Tapia, Mariana Dávila; Sánchez Sosa, Juan José; Robles, Óscar Cázares; Togawa, Carlos; Corrales Rascón, Andrés Ernesto // International Journal of Psychology & Psychological Therapy;2009, Vol. 9 Issue 1, p67 

    A cross-sectional study was made with the main objective to prove the effects of length of infection (in months) on predictors of adherence behaviors to antiretroviral therapy in a sample of 44 persons with HIV. A multiple linear regression analysis showed that motives and stress-related to high...

  • Attacking HIV Provirus: Therapeutic Strategies to Disrupt Persistent Infection. Margolis, David M.; Archin, Nancy M. // Infectious Disorders - Drug Targets;Dec2006, Vol. 6 Issue 4, p369 

    The therapeutic armamentarium for human immunodeficiency virus type 1 (HIV-1) infection continues to expand. New targets such as entry and integration have recently been successfully exploited. However, HIV-infected patients in need of treatment are currently committed to lifelong suppressive...

  • HIV-1 Infection and Central Monoamine Neurotransmitters. Kumar, Adarsh M.; Fernandez, J. B.; Borodowsky, Irina; Gonzalez, Louis; Kumar, Mahendra // American Journal of Infectious Diseases;2007, Vol. 3 Issue 4, p177 

    Human immunodeficiency virus type 1 (HIV-1) enters the central nervous system (CNS) shortly after infection and gets localized in different brain regions, leading to various types of neuropathological problems. It has been hypothesized that HIV-1 infection mediated neuropathogenesis may also...

  • Induction of a Soluble Anti-HIV-1 factor (s) with IFN-γ, IL-10, and β-Chemokine Modulating Activity by an Influenza-Bacterial Polyantigenic Mixture. Rodríguez, José W.; Pagan, Nat O.; Ocasio, María C.; Ríos, Zilka; Cubano, Luis A.; Boukli, Nawal M.; Otero, Miguel; Hunter, Robert; Nair, Madhavan P.; Rios-Olivares, Eddy // American Journal of Infectious Diseases;2007, Vol. 3 Issue 4, p266 

    Partial immune restoration may be obtained with highly active antiretroviral therapy (HAART), but specific anti-HIV-1 immune responses do not appear to improve substantially. We have demonstrated that a soluble factor(s) induced by a mixture of inactivated influenza and bacterial vaccines called...

  • Corroborative Study Confirmed That Adding Enfuvirtide to an Optimized Antiretroviral Regimen Benefited Patients with Multidrug-Resistant HIV Infection. Lorber, Bennett // Annals of Internal Medicine;12/7/2004, Vol. 141 Issue 11, p878 

    The article presents information on papers related to infectious diseases in Europe and Australia. The paper "Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia," by A. Lazzarin, B. Clotet, D. Cooper, et al. confirmed that adding enfuvirtide to an...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics